Abstracts tagged "Compliance"

Abstract Number: 2505 • 2015 ACR/ARHP Annual Meeting
A Fellow Led Quality Improvement Project for Improving Contraceptive Compliance in Women Receiving Teratogenic Medications
Melissa Wells¹, Victoria Lackey², Erica Peart³, Nicholas Holdgate⁴, Samya Mohammad¹, Stephen Balevic¹, Rebecca Sadun⁴, Lisa G. Criscione-Schreiber⁵, Megan E. B. Clowse³ and Mamata Yanamadala⁶, ¹Division of Rheumatology, Department of Medicine, Duke University, Durham, NC, ²Dept of Medicine, Division of Rheumatology, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC, ⁴Rheumatology, Duke University Medical Center, Durham, NC, ⁵Dept of Med/Rheum Div, Duke University, Durham, NC, ⁶Division of Geriatrics, Department of Medicine, Duke University, Durham, NC
Background/Purpose: Women of child bearing age with autoimmune diseases are often prescribed teratogenic medications. Contraceptive compliance in this group of patients has been shown to…
Abstract Number: 2633 • 2015 ACR/ARHP Annual Meeting
Association of Medication Beliefs, Self-Efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis
Caroline McCulley¹, Patricia P. Katz², Laura Trupin², Edward H. Yelin³ and Jennifer Barton^4,5, ¹Internal Medicine, Providence Portland Medical Center, Portland, OR, ²Rheumatology, UCSF, SF, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Rheumatology, OHSU, Portland, OR, ⁵Rheumatology, VA Portland Healthcare System, Portland, OR
Background/Purpose: Adherence to disease-modifying anti-rheumatic drugs (DMARDs) among rheumatoid arthritis (RA) patients ranges from 30% to 107%, leading to potential adverse outcomes. Patient beliefs about…
Abstract Number: 2649 • 2015 ACR/ARHP Annual Meeting
Test-Retest Reliability of the 5-Item Compliance Questionnaire Rheumatology and Factors Influencing Its Assessment of Adherence in Patients with Rheumatoid Arthritis
Raquel Sweezie¹, Mary J. Bell², Charles Goldsmith³, Imy Chiu¹, Anna Gutlin¹ and Sharron Sandhu¹, ¹Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ²Rheum Div/Univ of Toronto, University of Toronto, Toronto, ON, Canada, ³Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Adherence to disease modifying anti-rheumatic drug (DMARD) therapy is suboptimal in patients with rheumatoid arthritis (RA). Efficient, low-cost measures are required for optimal monitoring…
Abstract Number: 2758 • 2015 ACR/ARHP Annual Meeting
Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, John Isaacs³, Ann W. Morgan⁴, Anthony Wilson⁵, Kimme L. Hyrich⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Up to 40% of RA patients on anti-TNF agents fail to respond either due to primary or secondary inefficacy. One explanation is immunogenicity leading…
Abstract Number: 139 • 2015 ACR/ARHP Annual Meeting
One-Year Cost of Etanercept, Adalimumab, and Infliximab per Treated Patient with Chronic Inflammatory Arthritides in US Veterans
Brian Sauer¹, Chia-Chen Teng², Tao He³, Jianwei Leng⁴, Chao-Chin Lu⁵, Jessica Walsh⁶, Neel Shah⁷, David J. Harrison⁸, Derek Tang⁹ and Grant W. Cannon¹⁰, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁷1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁸Amgen Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Thousand Oaks, CA, ¹⁰Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Understanding the relative cost of tumor necrosis factor inhibitors (TNFi) can improve resource allocation from a payer’s perspective. Limited data exists in the VA…
Abstract Number: 382 • 2015 ACR/ARHP Annual Meeting
Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?
Christoph Hemmeler¹, Sabrina Morell², Paul Hasler¹ and Thomas Gross², ¹Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ²Traumatology, Kantonsspital Aarau, Aarau, Switzerland
Background/Purpose: Evidence shows that of ten patients taking medication against osteoporosis one will avoid subsequent fractures, decreasing the risk by > 50 %. On the…
Abstract Number: 469 • 2015 ACR/ARHP Annual Meeting
Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters
Virginia Pascual-Ramos¹ and Irazú Contreras-Yáñez², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The window of opportunity concept states that there are superior clinical responses and the potential for remission, when patients with rheumatoid arthritis (RA) are…
Abstract Number: 1032 • 2015 ACR/ARHP Annual Meeting
Adherence Patterns to American Academy of Ophthalmology Guidelines for Hydroxychloroquine Baseline Screening: Quality Assurance Assessment Utilizing Highmark Claims Data
Christina Payne¹, Patricia Gladowski², James Byers Jr.², Amy Tang³ and Mary Chester M. Wasko⁴, ¹Allegheny General Hospital Department of Medicine, Allegheny Health Network, Pittsburgh, PA, ²Enterprise Knowledge Discovery, Highmark Health, Pittsburgh, PA, ³Asthma, Allergy and Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁴Lupus Center, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial agent used commonly to treat selected autoimmune rheumatic diseases because of its therapeutic benefits, low cost, and favorable safety…
Abstract Number: 1198 • 2015 ACR/ARHP Annual Meeting
Design and Implementation of a Patient-Centered Navigator Program to Improve Adherence to Disease-Modifying Antirheumatic Drugs
Candace H. Feldman¹, Anarosa Campos², Alyssa Wohlfahrt², Yuanyu Lo², Joshua Gagne³, Maura D. Iversen⁴, Elena Massarotti⁵ and Daniel H. Solomon¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Northeastern University, Department of Physical Therapy, and Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Adherence is a complex behavior and rates among patients with rheumatic diseases are especially poor. To date, the impact of interventions on adherence and…
Abstract Number: 1203 • 2015 ACR/ARHP Annual Meeting
Patient Satisfaction and Outcomes of a NOVEL Ankylosing Spondylitis Education and Self-Management Project
Jean McQuade¹, Christina Johnston², Charles Inderjeeth^3,4,5,6, Kathy Briffa⁷, Jack Edelman⁸, Nicola Cook⁹ and Warren Raymond¹⁰, ¹Arthritis WA, Wembley, Australia, ²Arthritis and Osteoporosis WA, Perth, Austria, ³Rehabiltation and Aged care and Rheumatology, Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Australia, ⁴North Metropolitan Health Service, University of Western Australia, Perth, WA, Australia, ⁵Subiaco Rheumatology Clinic, Subiaco, Australia, ⁶Linear Clinical Research Ltd, Perth, Australia, ⁷School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia, ⁸Rheumatology, Sir Charles Gairdner Hospital, Perth, Australia, ⁹Royal Perth Hospital, Perth, Australia, ¹⁰Rheumatology and Geriatric Medicine, Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Australia
Background/Purpose : Disease specific self-management interventions are rare. After a needs assessment, focus group discussions, and Plan, Do, Study, Act (PDSA) model we developed and…
Abstract Number: 1496 • 2015 ACR/ARHP Annual Meeting
Uncovering and Addressing Issues Related to Medication Adherence Among Patients with Rheumatic Diseases: A Patient Navigator Pilot Program
Anarosa Campos¹, Alyssa Wohlfahrt¹, Yuanyu Lo¹, Maura D. Iversen², Elena Massarotti³, Daniel H. Solomon⁴ and Candace H. Feldman⁵, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Northeastern University, Department of Physical Therapy, and Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital,Harvard Medical School, Boston, MA
Background/Purpose: Poor adherence to medications is a common problem among rheumatology patients that can lead to irreversible negative outcomes. We piloted an intervention using patient…
Abstract Number: 1556 • 2015 ACR/ARHP Annual Meeting
The Medication Information-Seeking Behaviors of Rheumatoid Arthritis Patients Who Are Prescribed a New DMARD
Delesha Carpenter¹, Lorie Geryk², Courtney Arrindell³, Beth Jonas⁴ and Susan J. Blalock⁵, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Asheville, NC, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Research Ct, UNC-Chapel Hill, Chapel Hill, NC, ⁵School of Pharmacy, UNC at Chapel Hill, Chapel Hill, NC
Background/Purpose: We present preliminary longitudinal data about the information-seeking behaviors and medication experiences of RA patients who are prescribed a new DMARD. Methods: We recruited…
Abstract Number: 1652 • 2015 ACR/ARHP Annual Meeting
A HPLC-SRM-MS Based Method for the Detection of Adherence to Low-Dose Oral Methotrexate
James Bluett¹, Thierry Wendling², Kayode Ogungbenro², Isabel Riba-Garcia³, Richard Unwin³, Suzanne M. Verstappen⁴ and Anne Barton^5,6, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, The University of Manchester, Manchester, United Kingdom, ³Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Whilst methotrexate (MTX) is the first-line treatment of rheumatoid arthritis (RA), response is not universal. Rates of adherence reported in the literature range from…
Abstract Number: 2102 • 2015 ACR/ARHP Annual Meeting
Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Brian Sauer¹, Chia-Chen Teng², Jianwei Leng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Bradley S. Stolshek⁶, Derek Tang⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate [MTX] + hydroxychloroquine [HCQ] + sulfasalazine [SSZ]) and tumor necrosis factor…
Abstract Number: 2308 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Disease Prevention in RA: Compliance Lipid Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^3,4,5, Eric C. Sayre⁴, Michal Abrahamowicz⁶, John M. Esdaile^3,7,8 and Diane Lacaille^9,10,11, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Richmond, BC, Canada, ³Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ⁴Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁶Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰Arthritis Research Centre of Canada, Vancouver, BC, Canada, ¹¹University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of reduced quality of life and increased mortality in RA. Cardiovascular diseases are the leading cause of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].